Gunderson Dettmer client Frazier Healthcare Partners has led the $90 million financing of a biopharmaceutical firm focused on gastrointestinal issues created by Takeda Pharmaceutical. As part of the deal the new company, Phathom, will have control of development and exclusive commercial rights for an acid blocker known as vonoprazan.

In the announcement of the new venture Frazier Venture Partner Dr. Tachi Yamada said, “We are excited to have the opportunity to develop vonoprazan for the U.S., Europe and Canada to address this immense unmet need. Phathom represents a truly unique opportunity to launch a new company around a highly experienced, world-class team developing a late-stage product candidate supported by strong clinical data and commercial experience.”

The Gunderson Dettmer deal team was led by Tim Ehrlich and Albert Vanderlaan and included Jay Hachigian and Samantha Gross.